CoChat

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder

Open access
Scahill, Lawrence, McCracken, James T., King, Bryan H., Rockhill, Carol, Shah, Bhavik, Politte, Laura, Sanders, Roy, Minjarez, Mendy, Cowen, Jennifer, Mullett, Jennifer, Page, Chris, Ward, Denise, Deng, Yanhong, Loo, Sandra, Dziura, James, McDougle, Christopher J., Research Units on Pediatric Psychopharmacology Autism Network · 2015 · American Journal of Psychiatry

Abstract

OBJECTIVE: Hyperactivity, impulsiveness, and distractibility are common problems in children with autism spectrum disorder (ASD). Extended-release guanfacine is approved for children with attention deficit hyperactivity disorder but not well studied in ASD. METHOD: In a multisite, randomized clinical trial, extended-release guanfacine was compared with placebo in children with ASD accompanied by hyperactivity, impulsiveness, and distractibility. RESULTS: Sixty-two subjects (boys, N=53; girls, N=9; mean age=8.5 years [SD=2.25]) were randomly assigned to guanfacine (N=30) or placebo (N=32) for 8 weeks. The guanfacine group showed a 43.6% decline in scores on the Aberrant Behavior Checklist-hyperactivity subscale (least squares mean from 34.2 to 19.3) compared with a 13.2% decrease in the placebo group (least squares mean from 34.2 to 29.7; effect size=1.67). The rate of positive response (much improved or very much improved on the Clinical Global Impression-Improvement scale) was 50% (15 of 30) for guanfacine compared with 9.4% (3 of 32) for placebo. A brief cognitive battery tapping working memory and motor planning showed no group differences before or after 8 weeks of treatment. The modal dose of guanfacine at week 8 was 3 mg/day (range: 1-4 mg/day), and the modal dose was 3 mg/day (range: 2-4 mg/day) for placebo. Four guanfacine-treated subjects (13.3%) and four placebo subjects (12.5%) exited the study before week 8. The most common adverse events included drowsiness, fatigue, and decreased appetite. There were no significant changes on ECG in either group. For subjects in the guanfacine group, blood pressure declined in the first 4 weeks, with return nearly to baseline by endpoint (week 8). Pulse rate showed a similar pattern but remained lower than baseline at endpoint. CONCLUSIONS: Extended-release guanfacine appears to be safe and effective for reducing hyperactivity, impulsiveness, and distractibility in children with ASD.

Overview

Integrity signals

Registry

Crossref · 10.1176/appi.ajp.2015.15010055

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

4 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 38 references

Research works printed but not linked: 7

  1. American Psychiatric Association, 2000, Diagnostic and Statistical Manual of Mental Disorders-Text Revised
  2. Sparrow SS, 2005, Vineland-II Adaptive Behavior Scales
  3. Aman MG, 1985, Am J Ment Defic, 89, 485
  4. Elliott C, 2007, Differential Ability Scales-II (DAS-II)
  5. Korkman M, 2007, NEPSYII: Administration Manual
  6. Board AW, 1988, Clin Ther, 10, 761
  7. 10.1093/biostatistics/kxh001 · DOI · Paper page

Cited by

See all 218

Metadata

Authors
Scahill, L., McCracken, J. T., King, B. H., Rockhill, C., Shah, B., Politte, L., Sanders, R., Minjarez, M., Cowen, J., Mullett, J., Page, C., Ward, D., Deng, Y., Loo, S., Dziura, J., McDougle, C. J., & Research Units on Pediatric Psychopharmacology Autism Network
Affiliations
Seattle Children's Hospital (US)
Venue
American Journal of Psychiatry
Published
2015-12-01
Volume
172
Issue
12
Pages
1197-1206
ISSN
  • 0002-953X (ISSN-L)
  • 1535-7228
OpenAlex
W1933613998
Cited by
201
References
38
Citations by year
2026: 12 · 2025: 21 · 2024: 24 · 2023: 18 · 2022: 21 · 2021: 22 · 2020: 25 · 2019: 15 · 2018: 14 · 2017: 11 · 2016: 16 · 2015: 2
FWCI
8.62
Type
journal article
Language
en
Open access
Locations
  • American Journal of Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • Yale University
  • National Institutes of Health (UL1TR000454)
  • National Institute of Mental Health (R01MH86927, R01MH086927, R01MH83739, R01MH083707, R01MH083739, R01MH083747)
  • National Center for Research Resources (UL1RR024139)
  • National Center for Advancing Translational Sciences
Topics
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Health Sciences › Medicine › Psychiatry and Mental health › Child Nutrition and Feeding Issues
Keywords
guanfacine, autism spectrum disorder, hyperactivity, impulsivity, distractibility, ADHD medication, Aberrant Behavior Checklist, working memory, motor planning, blood pressure, adverse events, children
MeSH terms
Autism Spectrum Disorder, Adolescent, Child, Child, Preschool, Delayed-Action Preparations, Double-Blind Method, Female, Humans, Hyperkinesis, Male, Memory, Short-Term, Neuropsychological Tests, Psychomotor Performance, Guanfacine, Treatment Outcome, Adrenergic alpha-2 Receptor Agonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder. https://app.cochat.ai/papers/10.1176/appi.ajp.2015.15010055
The paper
Scahill, L., McCracken, J. T., King, B. H., Rockhill, C., Shah, B., Politte, L., Sanders, R., Minjarez, M., Cowen, J., Mullett, J., Page, C., Ward, D., Deng, Y., Loo, S., Dziura, J., McDougle, C. J., & Research Units on Pediatric Psychopharmacology Autism Network. (2015). Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.2015.15010055

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.